Home
/
GYRE THERAPEUTICS, INC.
/
Financials
/
Quarterly
GYRE THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that GYRE THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2015
Jun 30, 2015
$60.0K
Jul 31, 2015
Q1
2015
Mar 31, 2015
$60.0K
May 7, 2015
Q3
2014
Sep 30, 2014
$25.0K
Nov 6, 2014
Q2
2015
Jun 30, 2014
$36.0K
Jul 31, 2015
Q1
2015
Mar 31, 2014
$87.0K
May 7, 2015
Q3
2014
Sep 30, 2013
$3.54M
Nov 6, 2014
Q2
2014
Jun 30, 2013
$3.54M
Aug 7, 2014
Q1
2014
Mar 31, 2013
$3.54M
May 8, 2014
Q3
2013
Sep 30, 2012
$768.0K
Nov 6, 2013
Q2
2013
Jun 30, 2012
$33.65M
Aug 7, 2013
Q1
2013
Mar 31, 2012
$22.86M
May 8, 2013
Q3
2012
Sep 30, 2011
$18.96M
Nov 8, 2012
Q2
2012
Jun 30, 2011
$20.74M
Aug 9, 2012
Q1
2012
Mar 31, 2011
$38.99M
May 9, 2012
Q3
2011
Sep 30, 2010
$21.80M
Nov 3, 2011
Q2
2011
Jun 30, 2010
$20.90M
Aug 9, 2011
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$30.56M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$26.77M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$22.06M
May 9, 2025
Q3
2025
Sep 30, 2024
$25.49M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$25.23M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$27.17M
May 9, 2025
Q3
2024
Sep 30, 2023
$32.04M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$29.33M
Aug 13, 2024
Q1
2024
Mar 31, 2023
$24.93M
May 13, 2024
Q1
2022
Mar 31, 2022
$794.0K
May 9, 2022
Q3
2021
Sep 30, 2021
$2.30M
Nov 12, 2021
Q2
2021
Jun 30, 2021
$1.13M
Aug 5, 2021
Q1
2022
Mar 31, 2021
$1.47M
May 9, 2022
Q3
2021
Sep 30, 2020
$893.0K
Nov 12, 2021
Q2
2021
Jun 30, 2020
$1.66M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$16.37M
May 6, 2021
Q3
2019
Sep 30, 2018
$6.0K
Nov 7, 2019
Q2
2019
Jun 30, 2018
$6.0K
Aug 1, 2019
Q1
2019
Mar 31, 2018
$6.0K
May 2, 2019
Q3
2018
Sep 30, 2017
$318.0K
Nov 1, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$5.94M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$1.58M
Aug 11, 2025
Q3
2025
Jun 30, 2025
$1.58M
Nov 7, 2025
Q1
2025
Mar 31, 2025
$3.73M
May 9, 2025
Q3
2025
Mar 31, 2025
$3.73M
Nov 7, 2025
Q2
2025
Mar 31, 2025
$3.73M
Aug 11, 2025
Q3
2025
Sep 30, 2024
$2.86M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$4.54M
Aug 11, 2025
Q3
2025
Jun 30, 2024
$4.54M
Nov 7, 2025
Q1
2025
Mar 31, 2024
$9.94M
May 9, 2025
Q3
2025
Mar 31, 2024
$9.94M
Nov 7, 2025
Q2
2025
Mar 31, 2024
$9.94M
Aug 11, 2025
Q3
2024
Sep 30, 2023
$7.51M
Nov 13, 2024
Q3
2024
Jun 30, 2023
$3.77M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$3.77M
Aug 13, 2024
Q3
2024
Mar 31, 2023
$4.22M
Nov 13, 2024
Q1
2024
Mar 31, 2023
$4.22M
May 13, 2024
Q2
2024
Mar 31, 2023
$4.22M
Aug 13, 2024
Q3
2023
Sep 30, 2022
($4.88M)
Oct 26, 2023
Q2
2023
Jun 30, 2022
$51.63M
Aug 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$6.93M
Nov 7, 2025
Q2
2025
Jun 30, 2025
$2.17M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$2.27M
May 9, 2025
Q3
2025
Sep 30, 2024
$4.23M
Nov 7, 2025
Q2
2025
Jun 30, 2024
$3.19M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$8.07M
May 9, 2025
Q3
2024
Sep 30, 2023
$12.76M
Nov 13, 2024
Q2
2024
Jun 30, 2023
$4.97M
Aug 13, 2024
Q1
2024
Mar 31, 2023
$6.66M
May 13, 2024
Q3
2023
Sep 30, 2022
($5.17M)
Oct 26, 2023
Q2
2023
Jun 30, 2022
$51.53M
Aug 14, 2023
Q1
2023
Mar 31, 2022
($14.70M)
May 15, 2023
Q3
2022
Sep 30, 2021
($25.23M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($19.91M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($22.44M)
May 9, 2022
Q3
2021
Sep 30, 2020
($16.10M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($17.36M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($5.07M)
May 6, 2021
Q3
2020
Sep 30, 2019
($13.20M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($14.38M)
Aug 6, 2020